## Davide Roccarina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2981334/publications.pdf

Version: 2024-02-01

257101 243296 2,030 62 24 44 h-index citations g-index papers 62 62 62 3190 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Sex is a major effect modifier between body composition and mortality in patients with cirrhosis assessed for liver transplantation. Liver International, 2023, 43, 160-169.	1.9	4
2	How to perform shear wave elastography. Part I. Medical Ultrasonography, 2022, 24, 95.	0.4	26
3	How to perform shear wave elastography. Part II. Medical Ultrasonography, 2022, 24, 196.	0.4	13
4	Collagen proportionate area predicts long-term mortality in patients with alcoholic hepatitis. Digestive and Liver Disease, 2022, 54, 663-668.	0.4	3
5	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. Liver International, 2022, 42, 419-424.	1.9	4
6	Comparison of pointâ€shear wave elastography (ElastPQ) and transient elastography (FibroScan) for liver fibrosis staging in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 2195-2203.	1.9	3
7	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	1.8	33
8	Establishing Reliability Criteria for Liver ElastPQ Shear Wave Elastography (ElastPQ-SWE): Comparison Between 10, 5 and 3 Measurements. Ultraschall in Der Medizin, 2021, 42, 204-213.	0.8	9
9	Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013122.	1.5	10
10	Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013121.	1.5	7
11	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS ONE, 2021, 16, e0260313.	1.1	16
12	Defective spleen function in autoimmune gastrointestinal disorders. Internal and Emergency Medicine, 2020, 15, 225-229.	1.0	18
13	Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. American Journal of Gastroenterology, 2020, 115, 1911-1914.	0.2	38
14	Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis. Digestive and Liver Disease, 2020, 52, 761-767.	0.4	7
15	Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with lowâ∈moderate liver fibrosis. Journal of Viral Hepatitis, 2020, 27, 1214-1221.	1.0	7
16	Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2020, 1, CD013123.	1.5	11
17	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	1.8	97
18	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	1.8	47

#	Article	IF	CITATIONS
19	Collagen proportionate area predicts clinical outcomes in patients with alcoholâ€related liver disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1728-1739.	1.9	27
20	SAT-431-Spleen stiffness measurement with ElastPQ point shear wave elastography has an excellent performance in predicting the presence of clinically significant portal hypertension in primary biliary cholangitis. Journal of Hepatology, 2019, 70, e825.	1.8	0
21	THU-309-Cardiovascular risk assessment and management improves outcomes in a specialist multidisciplinary non-alcoholic fatty liver disease clinic. Journal of Hepatology, 2019, 70, e296.	1.8	1
22	SAT-016-Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites. Journal of Hepatology, 2019, 70, e632.	1.8	3
23	SAT-108-Sarcopenia and nutritional status predict mortality in patients with cirrhosis undergoing liver transplant assessment. Journal of Hepatology, 2019, 70, e676.	1.8	0
24	GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival. Journal of Hepatology, 2019, 70, e84.	1.8	4
25	THU-337-Cardiovascular risk factors and fibrosis severity in NAFLD: is there a link?. Journal of Hepatology, 2019, 70, e308.	1.8	0
26	SAT-430-Spleen stiffness measured with ElastPQ point shear wave elastography has a good performance in predicting clinically significant portal hypertension in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e824-e825.	1.8	0
27	SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis. Journal of Hepatology, 2019, 70, e670.	1.8	0
28	Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. European Journal of Clinical Investigation, 2019, 49, e13088.	1.7	14
29	OTU-12â€Spleen stiffness has a good performance in predicting clinically significant portal hypertension in PSC. , 2019, , .		0
30	PTU-034 $\hat{a}$ Spleen stiffness by elastPQ point shear wave elastography predicts clinically significant portal hypertension in PBC. , 2019, , .		0
31	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2019, 9, CD013120.	1.5	7
32	Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 474-480.	0.9	18
33	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 446-452.	0.2	65
34	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	0.6	82
35	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	0.6	162
36	MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. Hepatology, 2018, 68, 172-186.	3.6	129

#	Article	IF	Citations
37	Elastography methods for the non-invasive assessment of portal hypertension. Expert Review of Gastroenterology and Hepatology, 2018, 12, 155-164.	1.4	54
38	Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. American Journal of Gastroenterology, 2017, 112, 588-596.	0.2	82
39	Management of people with intermediate-stage hepatocellular carcinoma. The Cochrane Library, 2017, 3, CD011649.	1.5	16
40	Management of people with early- or very early-stage hepatocellular carcinoma. The Cochrane Library, 2017, 3, CD011650.	1.5	59
41	Spleen Stiffness in Myeloproliferative Disease Related Splanchnic Vein Thrombosis. Blood, 2016, 128, 5468-5468.	0.6	1
42	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World Journal of Gastroenterology, 2015, 21, 11044.	1.4	25
43	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World Journal of Hepatology, 2015, 7, 1866.	0.8	24
44	Clinical effects of Helicobacter pylori outside the stomach. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 234-242.	8.2	137
45	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. Journal of Hepatology, 2013, 59, 1014-1021.	1.8	75
46	Author reply: Comment to "Different Antibiotic No Culture Eradicating (DANCE) strategy: An easy way to manage H. pylori eradication― Digestive and Liver Disease, 2013, 45, 438-439.	0.4	0
47	Diagnosis of bowel diseases: The role of imaging and ultrasonography. World Journal of Gastroenterology, 2013, 19, 2144.	1.4	25
48	Impact of <i>Lactobacillus reuteri</i> Supplementation on Anti- <i>Helicobacter pylori</i> Levofloxacin-Based Second-Line Therapy. Gastroenterology Research and Practice, 2012, 2012, 1-6.	0.7	64
49	Different Antibiotic No Culture Eradicating (DANCE) strategy: An easy way to manage H. pylori eradication. Digestive and Liver Disease, 2012, 44, 889-892.	0.4	10
50	What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. World Journal of Gastroenterology, 2012, 18, 5014.	1.4	46
51	Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. World Journal of Gastroenterology, 2012, 18, 6693.	1.4	46
52	The Role of Methane in Intestinal Diseases. American Journal of Gastroenterology, 2010, 105, 1250-1256.	0.2	89
53	Probiotics and H. pylori Infection. , 2010, , 259-265.		0
54	Helicobacters and Extragastric Diseases. Helicobacter, 2009, 14, 58-68.	1.6	65

#	Article	IF	CITATIONS
55	CagA antigen of helicobacter pylori and coronary instability: Insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis, 2009, 202, 535-542.	0.4	95
56	Extragastric Manifestations of <i>Helicobacter pylori</i> Infection: Other <i>Helicobacters</i> Helicobacter, 2008, 13, 47-57.	1.6	30
57	Celiac Disease: What's New about It?. Digestive Diseases, 2008, 26, 121-127.	0.8	24
58	Celiac Disease and Myointimal Proliferation: A Possible Correlation?. Case Reports in Gastroenterology, 2008, 2, 398-404.	0.3	2
59	Extragastric Manifestations of <i>Helicobacter pylori</i> Infection – Other <i>Helicobacters</i> Helicobacter, 2007, 12, 45-53.	1.6	44
60	Role of Probiotics in Patients with <i>Helicobacter pylori</i> Infection. Helicobacter, 2007, 12, 59-63.	1.6	54
61	Extragastric Manifestations of Helicobacter pylori Infection – Other Helicobacter Species. Helicobacter, 2006, 11, 46-51.	1.6	67
62	infection and ischaemic heart disease: An overview of the general literature. Digestive and Liver Disease, 2005, 37, 301-308.	0.4	31